AR068107A1 - Derivados indolicos 2,3 sustituidos y una composicion farmaceutica - Google Patents

Derivados indolicos 2,3 sustituidos y una composicion farmaceutica

Info

Publication number
AR068107A1
AR068107A1 ARP080103716A ARP080103716A AR068107A1 AR 068107 A1 AR068107 A1 AR 068107A1 AR P080103716 A ARP080103716 A AR P080103716A AR P080103716 A ARP080103716 A AR P080103716A AR 068107 A1 AR068107 A1 AR 068107A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
heterocycloalkyl
independently
aryl
Prior art date
Application number
ARP080103716A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR068107A1 publication Critical patent/AR068107A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La presente se refiere a derivados indolicos 2,3 sustituidos, composiciones que comprenden por lo menos un derivado indolico 2,3 sustituido. Estos compuestos son utiles para tratar o prevenir una infeccion viral o un trastorno relacionado con un virus en un paciente. Reivindicacion 1: Un compuesto que tiene la formula (1) o una de sus sales, solvatos, ésteres o prodrogas aceptable desde el punto de vista farmacéutico en los cuales R1 es un enlace, -[C(R12)2]r-, -[C(R12)2]r-O-[C(R12)2]q-, -[C(R12)2]r-N(R9)-[C(R12)2]q-, -[C(R12)2]q-CH=CH-[C(R12)2]q-, -[C(R12)2]q-C:::C-[C(R12)2]q- o -[C(R12)2]q-SO2-[C(R12)2]q-; R2 es -[C(R12)2]q-C(O)N(R9)SOR11, -[C(R12)2]q-C(O)N(R9)SO2R11, -[C(R12)2]q-C(O)N(R9)SO2N(R9)2, o como los compuestos de formulas (2); R3 es como los compuestos de formulas (3), R4, R5, R6 y R7 son cada uno, independientemente, H, alquilo, alqueniIo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, -OH, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 o -SO2N(R9)C(O)N(R9)2; cada vez que ocurre R8 es en forma independiente H, alquilo, alquenilo, alquinilo, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, haloalquilo, o hidroxialquilo, cada vez que ocurre R9 es en forma independiente H, alquilo, alquenilo, alquinilo, -[C(R12)2]q-O-alquilo, -[C(R12)2]q-N(alquil)2, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, haloalquilo o hidroxialquilo; R10 es H, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo o heteroarilo puede estar sustituido en forma independiente y opcional con hasta 4 sustituyentes, que se seleccionan en forma independiente de H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo,-[C(R12)2]q-haloalquiIo, -[C(R12)2]q-hidroxialquilo, halo, -OH, -OR9, -CN, -NO2, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; de manera tal que cuando R1 es un enlace, R10 no es H; cada vez que ocurre R11 es en forma independiente alquilo, arilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, heteroarilo, haloalquilo, hidroxi, o hidroxialquilo, donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo o heteroarilo puede estar sustituido en forma independiente y opcional con hasta 4 sustituyentes que se seleccionan en forma independiente de H, alquilo, alqueniIo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, -OH, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2alquilo, -[C(R12)2]q-NHSO2cicloalquilo, -[C(R12)2]q-NHSO2arilo, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; cada vez que ocurre R12 es en forma independiente H, halo, -N(R9)2, -OR9, alquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo puede estar sustituido en forma independiente y opcional con hasta 4 sustituyentes, que se seleccionan en forma independiente de alquilo, halo, haloalquilo, hidroxialquilo, -OH, -CN, -C(O)alquilo, -C(O)Oalquilo, -C(O)NH-alquilo, -C(O)N(alquilo)2, -O-alquilo, -NH2, -NH(alquilo), -N(alquil)2, -NHC(O)alquilo, -NHSO2alquilo, -SO2alquilo o -SO2NH-alquilo, o dos grupos R12, junto con los átomos de carbono a los cuales están unidos, se unen para formar un grupo cicloalquilo, heterocicloalquilo o C=O; cada vez que ocurre R20 es en forma independiente alquilo, arilo, cicloalquilo, heterocicloalquilo o heteroarilo, o ambos grupos R20 y los átomos de C a los cuales están unidos, se unen para formar un grupo cicloalquilo, cicloheteroalquilo, arilo o heteroarilo donde un grupo cicloalquilo, cicloheteroalquilo, arilo o heteroarilo puede estar sustituido con hasta 4 grupos, que se seleccionan en forma independiente de alquilo, alquenilo, alquinilo, halo, -OH, -OR9, -CN, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; cada vez que ocurre R30 es en forma independiente H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, -OH, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 o -SO2N(R9)C(O)N(R9)2, o dos grupos R30 adyacentes, junto con los átomos de carbono a los cuales están unidos, se unen para formar un anillo de 3 a 7 miembros seleccionado entre arilo, cicloalquilo, heteroarilo y heterocicloalquilo; cada vez que ocurre p es en forma independiente 0, 1 o 2; cada vez que ocurre q es en forma independiente un numero entero que varía desde 0 hasta 4; y cada vez que ocurre r es en forma independiente un numero entero que varía desde 1 hasta 4.
ARP080103716A 2007-08-29 2008-08-27 Derivados indolicos 2,3 sustituidos y una composicion farmaceutica AR068107A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96874507P 2007-08-29 2007-08-29

Publications (1)

Publication Number Publication Date
AR068107A1 true AR068107A1 (es) 2009-11-04

Family

ID=40220015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103716A AR068107A1 (es) 2007-08-29 2008-08-27 Derivados indolicos 2,3 sustituidos y una composicion farmaceutica

Country Status (18)

Country Link
US (1) US8143305B2 (es)
EP (1) EP2197842B1 (es)
JP (1) JP5272007B2 (es)
KR (1) KR20100049667A (es)
CN (1) CN101842353A (es)
AR (1) AR068107A1 (es)
AU (1) AU2008295476B2 (es)
BR (1) BRPI0816116A2 (es)
CA (1) CA2697375A1 (es)
CL (1) CL2008002538A1 (es)
CO (1) CO6321236A2 (es)
EC (1) ECSP10010002A (es)
MX (1) MX2010002319A (es)
PE (1) PE20090995A1 (es)
RU (1) RU2010111550A (es)
TW (1) TW200924751A (es)
WO (1) WO2009032116A1 (es)
ZA (1) ZA201001335B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
US8557848B2 (en) 2006-12-22 2013-10-15 Merck Sharp & Dohme Corp. 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
CN101611025A (zh) 2006-12-22 2009-12-23 先灵公司 5,6-环化的吲哚衍生物及其使用方法
WO2008082488A1 (en) 2006-12-22 2008-07-10 Schering Corporation 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
RU2010111551A (ru) * 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) Замещенные индольные производные и способы их применения
JP5258889B2 (ja) * 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
JP5416708B2 (ja) * 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
US8901139B2 (en) * 2008-06-13 2014-12-02 Merck Sharp & Dohme Corp. Tricyclic indole derivatives and methods of use thereof
PE20110409A1 (es) 2008-07-23 2011-06-22 Hoffmann La Roche Compuestos heterociclicos antiviricos
BRPI0920513A2 (pt) 2008-09-26 2019-09-24 F Hoffamann La Roche Ag derivados de pirina ou pirazina para tratar hcv
BRPI1016167A2 (pt) 2009-04-25 2019-07-16 Hoffmann La Roche compostos heterocíclicos antivirais.
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
AU2010264802A1 (en) 2009-06-24 2012-01-19 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
CA2768924A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011049988A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
CA2830780A1 (en) 2011-03-22 2012-09-27 Amgen Inc. Azole compounds as pim inhibitors
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2013130703A2 (en) * 2012-02-29 2013-09-06 Institute For Hepatitis And Virus Research Binhibitors of hepatitis b virus convalently closed circular dna formation and their method of use
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2909209B1 (en) 2012-10-17 2022-08-03 Merck Sharp & Dohme LLC 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2909210A4 (en) 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
RU2015123641A (ru) 2012-11-19 2017-01-10 Мерк Шарп И Доум Корп. 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
EP3010512B1 (en) 2013-06-18 2017-12-27 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
WO2014205592A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof for treatment of hepatitis c
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
CN105254617A (zh) * 2014-07-16 2016-01-20 南开大学 抗丙型肝炎病毒(hcv)吲哚类化合物及其制备方法和用途
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
CA2988572A1 (en) 2015-06-26 2016-12-29 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
EP3471737A4 (en) 2016-06-20 2019-12-25 Merck Sharp & Dohme Corp. CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE COMPOUND AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
CN109803951B (zh) * 2016-11-08 2020-12-04 正大天晴药业集团股份有限公司 作为cccDNA抑制剂的磺酰胺类化合物
MA54847A (fr) 2016-12-09 2021-12-08 Vertex Pharma Forme crystalline d'un n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide pour traiter la mucoviscidose
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
US10988454B2 (en) * 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE648639C (de) 1935-05-19 1937-08-05 I G Farbenindustrie Akt Ges Verfahren zur Darstellung von Dipyrrolen
US3632805A (en) * 1967-12-08 1972-01-04 Sumitomo Chemical Co Process for producing 1-aminoalkyl-benzodiazepine derivatives
AU575854B2 (en) * 1983-10-04 1988-08-11 Shionogi & Co., Ltd. 7beta-(carboxyalkenamido) cephalosporins
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US5017380A (en) * 1986-07-02 1991-05-21 Shionogi & Co., Ltd. Gelatin hard capsule containing crystalline hydrate of oral cephalosporin
CA2038925A1 (en) 1990-03-26 1991-09-27 Takashi Sohda Indole derivatives, their production and use
JPH04149429A (ja) 1990-10-12 1992-05-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法
IT1278077B1 (it) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ATE283865T1 (de) 1997-08-11 2004-12-15 Boehringer Ingelheim Ca Ltd Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
KR20030036152A (ko) * 2000-04-05 2003-05-09 쉐링 코포레이션 Ｎ-사이클릭 ｐ2 잔기를 포함하는 ｃ형 간염 바이러스의매크로사이클릭 ｎｓ3-세린 프로테아제 억제제
MXPA02010375A (es) * 2000-04-19 2003-04-25 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa del virus de la hepatitis c que comprenden porciones alquil y arilalanina p2.
AR034127A1 (es) * 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
CZ2003195A3 (cs) * 2000-07-21 2003-04-16 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostředek
PL206255B1 (pl) * 2000-07-21 2010-07-30 Dendreon Corporationdendreon Corporation Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
EP1341761A1 (en) 2000-10-10 2003-09-10 Smithkline Beecham Corporation SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS
CA2430458A1 (en) * 2000-12-12 2002-06-20 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
EP1349834A2 (en) * 2000-12-18 2003-10-08 Eli Lilly And Company Cycloalkyfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
ATE378328T1 (de) 2001-02-22 2007-11-15 Univ London Pharmacy Pyrrolo-indol- und pyrrolo-chinolin-derivate als prodrugs zur tumorbehandlung
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US20050215614A1 (en) 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
DK1644363T3 (da) 2003-05-30 2012-05-29 Gemin X Pharmaceuticals Canada Inc Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp ANTI-INTERLEUKIN ANTIBODY-10
PT1730110E (pt) 2004-02-27 2010-09-14 Schering Corp Compostos de enxofre como inibidores de serina-protease ns3 do vírus da hepatite c
AU2005218553A1 (en) 2004-03-01 2005-09-15 Viropharma Incorporated Pyranoindole derivatives and the use thereof for the treatment of Hepatitis C virus infection or disease
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7250441B2 (en) 2004-09-23 2007-07-31 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
DE102004047272A1 (de) 2004-09-24 2006-04-06 Schering Ag Inhibitoren der löslichen Adenylatzyklase
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
JP4149429B2 (ja) 2004-10-26 2008-09-10 本田技研工業株式会社 車両の走行安全装置
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2008004024A (es) 2005-09-23 2009-02-27 Schering Corp Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos.
JP2009523732A (ja) * 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
US8557848B2 (en) * 2006-12-22 2013-10-15 Merck Sharp & Dohme Corp. 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections

Also Published As

Publication number Publication date
ZA201001335B (en) 2010-12-29
JP5272007B2 (ja) 2013-08-28
KR20100049667A (ko) 2010-05-12
AU2008295476B2 (en) 2013-08-01
US20110033417A1 (en) 2011-02-10
EP2197842A1 (en) 2010-06-23
PE20090995A1 (es) 2009-08-03
WO2009032116A1 (en) 2009-03-12
AU2008295476A1 (en) 2009-03-12
US8143305B2 (en) 2012-03-27
RU2010111550A (ru) 2011-10-10
CN101842353A (zh) 2010-09-22
CO6321236A2 (es) 2011-09-20
CA2697375A1 (en) 2009-03-12
BRPI0816116A2 (pt) 2015-03-03
ECSP10010002A (es) 2010-03-31
JP2010537979A (ja) 2010-12-09
CL2008002538A1 (es) 2009-07-17
EP2197842B1 (en) 2012-05-23
TW200924751A (en) 2009-06-16
MX2010002319A (es) 2010-03-22

Similar Documents

Publication Publication Date Title
AR068107A1 (es) Derivados indolicos 2,3 sustituidos y una composicion farmaceutica
AR068108A1 (es) Derivados azaindol 2,3-sustituidos y una composicion farmaceutica
AR068106A1 (es) Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica
AR068109A1 (es) Derivados tetraciclicos de indol y una composicion farmaceutica
AR064428A1 (es) Derivados indolicos con anillo unido en las posiciones 4,5 y sus metodos de uso. composiciones farmaceuticas
AR064429A1 (es) Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales.
AR064430A1 (es) Derivados indolicos con anillo unido en las posiciones 5,6 . composiciones farmaceuticas y uso de los mismos.
AR114044A1 (es) Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR048537A1 (es) Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.
AR049170A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR101106A1 (es) Inhibidores de tirosina quinasa de bruton
AR051469A1 (es) Derivados de indol tetraciclicos como agentes antiviricos
AR103252A1 (es) Compuestos de quinazolina
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
AR058379A1 (es) Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
SI2997033T1 (en) FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
AR063545A1 (es) Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer
AR042956A1 (es) Inhibidores de girasa y usos de los mismos
PE20160501A1 (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
AR066911A1 (es) Derivados de piperidina / piperazina
AR066459A1 (es) Derivados de oxadiazol como moduladores de gamma-secretasa. composiciones farmaceuticas
AR082573A1 (es) Derivados de piperidina, composiciones farmaceuticas y sus usos para el tratamiento de cancer
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR076024A1 (es) Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure